All In Biotech

Drug Trial Radar · NCT05060432

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

153

Actual

Start

Sep 6, 2021

Primary completion

Jul 2024

Study completion Jul 2025

Sponsor

Lead sponsor
iTeos Belgium SAIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline; iTeos Therapeutics
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

Conditions

  • Advanced Cancer
  • Lung Cancer
  • Head and Neck Cancer
  • Melanoma

Interventions

  • EOS-448Drug

    Anti-TIGIT monoclonal antibody

  • pembrolizumabDrug

    Anti-PD-1 monoclonal antibody

  • inupadenantDrug

    A2A receptor antagonist

  • DostarlimabDrug

    Anti-PD-1 monoclonal antibody

  • SOC chemotherapiesDrug

    SOC chemotherapies in 1L mNSCLC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with DLT and Adverse EventsTime frame: From first study treatment administration through Day 21-28 for DLT / Up to 120 days after the last dose
  2. Recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced solid tumorsTime frame: Up to 48 weeks
  3. Percentage of participants with Objective Response as determined by InvestigatorTime frame: Until disease progression - Approximately 48 months

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    San Diego, California

  • Hackensack University Medical Center

    Bergen, New Jersey

  • Cliniques universitaires St Luc-UCL

    Brussels, Belgium

  • Jessa Ziekenhuis

    Hasselt, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU Helora

    Mons, Belgium

  • GZA Ziekenhuizen campus Sint-Augustinus

    Antwerp, Antwerp, Belgium

  • Hôpital Saint André

    Bordeaux, France

  • CHU Caen

    Caen, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Clinique Victor Hugo

    Le Mans, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Institut de Cancerologie Lorraine (ICL)

    Nancy, France

  • Institut de Cancérologie de l'Ouest

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Pitié Salpêtrière

    Paris, France

  • CHU de POITIERS

    Poitiers, France

  • ICANS

    Strasbourg, France

  • Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • AUSL Della Romagna - Ospedale S. Maria delle Croci

    Ravenna, Italy

  • IDB Center-Istituto Clinico Humanitas (IRCCS)

    Rozzano, Milan, Italy

  • FPO-IRCCS Candiolo Cancer Insitute

    Candiolo, Turin, Italy

  • Hospital Universitario de Badajoz

    Badajoz, Spain

  • Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario de Jaen

    Jaén, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz - START Madrid

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Quirón Málaga

    Málaga, Spain

  • Hospital Universitario de Navarra

    Pamplona, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Fundacion Instituto Valenciano de Oncologia (IVO)

    Valencia, Spain

  • Consorci Hospital Gral Univ Valencia

    Valencia, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)

    Valencia, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hospital Althaia Xarxa Assitencial de Manresa

    Manresa, Catalonia, Spain

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Royal Marsden Hospital (London location)

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.